Abstract
Gastric cancer is among the leading lethal cancer types in the world. However, its five year survival rate is far from satisfactory. Therefore, the development of targeted cancer gastric cancer therapy is a promising way to cure gastric cancer. Gastric cancer exosome is reported to have high caner targeting efficacy, but its yield is relatively low. Herein, we proposed a facile way to construct hybrid gastric cancer exosome (HGCE) with high yield as potential drug carrier for targeted gastric cancer therapy. The doxorubicin (Dox) loaded HGCE (Dox/HGCE) was developed as drug delivery system (DDS) to treat gastric cancer. In vitro and in vivo results demonstrated that Dox/HGCE showed not only high and specific homing ability to the gastric cancer cells (SGC7901) but also good anticancer performance which can be a promising DDS for gastric cancer therapy.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
